Safety evaluation of recombinant human interleukin-4. I. Preclinical studies

Clinical Immunology and Immunopathology

Volumn 83, Issue 1, 1997, Pages 8-11

  Leach, Michael W ^a   Snyder, Eileen A ^a   Sinha, Dinesh P ^a   Rosenblum, I Y ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 4;

ANIMAL MODEL; CONFERENCE PAPER; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOXICITY;

EID: 0031127471     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4303     Document Type: Conference Paper

References (38)

1. 1. Banchereau, J., Brière, F., Galizzi, J. P., Miossec, P., and Rousset, F., Human interleukin 4. J. Lipid Mediators Cell Signalling 1994.
2. 2. Banchereau, J., and Rybak, M. E., Interleukin-4. In "The Cytokine Handbook" (A. W. Thomson, Ed.), pp. 99-126, Academic Press, London, 1994.
3. 3. Paul, W. E., Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77, 1859-1870, 1991.
4. 4. Street, N. E., and Mosmann, T. R., IL4 and IL5: The role of two multifunctional cytokines and their place in the network of cytokine interactions. Biotherapy 2, 347-362, 1990.
5. 5. Lahm, H., Schnyder, B., Wyniger, J., Borbenyi, Z., Yilmaz, A., Car, B. D., Fischer, J. R., Givel, J.-C., and Ryffel, B., Growth inhibition of human colorectal-carcinoma cells by interleukin-4 and expression of functional interleukin-4 receptors. Int. J. Cancer 59, 440-447, 1994.
6. 6. Hillman, G. G., Younes, E., Visscher, D., Ali, E., Lam, J. S., Montecillo, E., Pontes, J. E., Haas, G. P., and Puri, R. K., Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cell. Immunol. 160, 257-263, 1995.
7. 7. Rybak, M. E., and Catino, J. J., An overview of the clinical use of recombinant human interleukin-4. In "Cytokines in Hematopoiesis, Oncology, and Immunology III" (M. Freund, H. Link, R. Schmidt, and K. Welte, Eds.), pp. 39-45, Springer-Verlag, Berlin, 1994.
8. 8. Tepper, R. I., The eosinophil-mediated antitumor activity of interleukin-4. J. Allergy Clin. Immunol. 94, 1225-1231, 1994.
9. 9. Younes, E., Haas, G. P., Visscher, D., Pontes, J. E., Puri, R. K., and Hillman, G. G., Intralesional treatment of established murine primary renal tumor with interleukin-4: Localized effect on primary tumor with no impact on metastases. J. Urol. 153, 490-493, 1995.
10. 10. Andus, T., Bauer, J., and Gerok, W., Effects of cytokines on the liver. Hepatology 13, 364-375, 1994.
11. 11. Mosmann, T. R., Yokota, T., Kastlelein, R., Zurawski, S. M., Arai, N., and Takebe, Y., Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): Comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4). J. Immunol. 138, 1813-1816, 1987.
12. 12. Snyder, E., Leach, M., Sinha, D., Halliwell, W., McCullough, B., and Rosenblum, I., Effects of subcutaneous rhuIL-4 in cynomolgus monkeys. Fundam. Appl. Toxicol. (Suppl.) 30, 107-108, 1996.
13. 13. Leach, M., Snyder, E., Sinha, D., Halliwell, W., McCullough, B., and Rosenblum, I., Pathologic findings in cynomolgus monkeys administered IL-4. Fundam. Appl. Toxicol. (Suppl.) 30, 107, 1996.
14. 14. Colotta, F., Sironi, M., Borré, A., Luini, W., Maddalena, F., and Mantovani, A., Interleukin 4 amplifies monocyte chemotactic protein and interleukin 6 production by endothelial cells. Cytokine 4, 24-28, 1992.
15. 15. Masinovsky, B., Urdal, D., and Gallatin, W. M., IL-4 acts synergistically with IL-1b to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J. Immunol. 145, 2886-2895, 1990.
16. 16. Schleimer, R. P., Sterbinsky, S. A., Kaiser, J., Bickel, C. A., Klunk, D. A., Tomioka, K., Newman, W., Luscinskas, F. W., Gimbrone, M. A. J., McIntyre, B. W., and Bochner, B. S., IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. J. Immunol. 148, 1086-1092, 1992.
17. 17. Nakajima, H., Sano, H., Nishimura, T., Yoshida, S., and Iwamoto, I., Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue. J. Exp. Med. 179, 1145-1154, 1994.
18. 18. Briscoe, D. M., Cotran, R. S., and Pober, J. S., Effects of tumor necrosis factor, lipopolysaccharide, and IL-4 on the expression of vascular cell adhesion molecule-1 in vivo. J. Immunol. 149, 2954-2960, 1992.
19. 19. Tsuji, K., Nakahata, T., Takagi, M., Kobayashi, T., Ishiguro, A., Kikuchi, T., Naganuma, K., Koike, K., Miyajima, A., Arai, K.-I., and Akabane, T., Effects of interleukin-3 and interleukin-4 on the development of "connective tissue-type" mast cells: Interleukin-3 supports their survival and interleukin-4 triggers and supports their proliferation synergistically with interleukin-3. Blood 75, 421-427, 1990.
20. 20. Mosmann, T. R., Bond, M. W., Coffman, R. L., Ohara, J., and Paul, W. E., T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA 83, 5654-5658, 1986.
21. 21. Rennick, D., Yang, G., Muller-Sieburg, C., Smith, C., Arai, N., Takabe, Y., and Gemmell, L., Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 84, 6889-6893, 1987.
22. 22. Peschel, P., Paul, W. E., Ohara, J., and Green, I., Effects of B cell stimulatory factor-1/interleukin 4 on hematopoietic progenitor cells. Blood 70, 254-263, 1987.
23. 23. Jacobsen, F. W., Keller, J. R., Ruscetti, F. W., Veiby, O. P., and Jacobsen, S. E. W., Direct synergistic effects of IL-4 and IL-11 on proliferation of primitive hematopoietic progenitor cells. Exp. Hematol. 23, 990-995, 1995.
24. 24. Postlethwaite, A. E., and Seyer, J. M., Fibroblast chemotaxis induction by human recombinant interleukin-4. J. Clin. Invest. 87, 2147-2152, 1991.
25. 25. Postlethwaite, A. E., Holness, M. A., Katai, H., and Raghow, R., Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90, 1479-1485, 1992.
26. 26. Gillery, P., Fertin, C., Nicolas, J. F., Chastang, F., Kalis, B., Banchereau, J., and Maquart, F. X., Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett. 302, 231-234, 1992.
27. 27. Tiggleman, A. M. B. C., Boers, W., Linthorst, C., Sala, M., and Chamuleau, R. A. F. M., Collagen synthesis by human liver (myo)fibroblasts in culture: Evidence for a regulatory role of IL-1b, IL-4, TGFb, and INF gamma. J. Hepatol. 23, 307-317, 1995.
28. 28. Suzuki, A., Takahashi, T., Okuno, Y., Seko, S., Fukuda, Y., Nakamura, K., Fukumoto, M., Konaka, Y., and Imura, H., Liver damage in patients with colony-stimulating factor-producing tumors. Am. J. Med. 94, 125-132, 1993.
29. 29. Howells, G., Pham, P., Taylor, D., Foxwell, B., and Feldmann, M., Interleukin 4 induces interleukin 6 production by endothelial cells: Synergy with interferon-γ. Eur. J. Immunol. 21, 97-101, 1991.
30. 30. Toi, M., Harris, A. L., and Bicknell, R., Interleukin-4 is a potent mitogen for capillary endothelium. Biochem. Biophys. Res. Commun. 174, 1287-1293, 1991.
31. 31. Means, R. T., Jr., Pathogenesis of anemia of chronic disease: A cytokine-mediated anemia. Stem Cells 13, 32-37, 1995.
32. 32. Loyer, P., Ilyin, G., Razzak, Z. A., Banchereau, J., Dezier, J.-F., Campion, J.-P., Guguen-Guillouzo, C., and Guillouzo, A., Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett. 336, 215-220, 1993.
33. 33. Hill, M. R., Stith, R. D., and McCallum, R. E., Interleukin 1: A regulatory role in glucocorticoid-regulated hepatic metabolism. J. Immunol. 137, 858-862, 1986.
34. 34. Barbolt, T. A., Gossett, K. A., and Cornacoff, J. B., Histomorphologic observations for cynomolgus monkeys after subchronic subcutaneous injection of recombinant human interleukin-4. Toxicol. Pathol. 19, 251-257, 1991.
35. 35. Dean, J. H., Cornacoff, J. B., Barbolt, T. A., Gossett, K. A., and LaBrie, T., Pre-clinical toxicity of IL-4: A model for studying protein therapeutics. Int. J. Immunopharmacol. 14, 391-397, 1992.
36. 36. Gossett, K. A., Barbolt, T. A., Cornacoff, J. B., Zelinger, D. A., and Dean, J. H., Clinical pathologic alterations associated with subcutaneous administration of recombinant human interleukin-4 to cynomolgus monkeys. Toxicol. Pathol. 21, 46-53, 1993.
37. 37. Cornacoff, J. B., Gossett, K. A., Barbolt, T. A., and Dean, J. H., Preclinical evaluation of recombinant human interleukin-4. Toxicol. Lett. 64/65, 299-310, 1993.
38. 38. Leach, M. W., Rybak, M. E., and Rosenblum, I. Y., Safety evaluation of recombinant human interleukin-4. II. Clinical studies. Clin. Immunol. Immunopathol. 83, 12-14, 1997.